Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Invested Capital (2016 - 2025)

Adma Biologics' Invested Capital history spans 14 years, with the latest figure at $480.1 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 37.57% year-over-year to $480.1 million; the TTM value through Dec 2025 reached $480.1 million, up 37.57%, while the annual FY2025 figure was $480.1 million, 37.57% up from the prior year.
  • Invested Capital reached $480.1 million in Q4 2025 per ADMA's latest filing, up from $433.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $480.1 million in Q4 2025 to a low of $100.4 million in Q3 2022.
  • Average Invested Capital over 5 years is $207.5 million, with a median of $149.1 million recorded in 2023.
  • Peak YoY movement for Invested Capital: fell 11.03% in 2023, then skyrocketed 158.14% in 2024.
  • A 5-year view of Invested Capital shows it stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then fell by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then skyrocketed by 37.57% to $480.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Invested Capital are $480.1 million (Q4 2025), $433.5 million (Q3 2025), and $398.3 million (Q2 2025).